| Ytd | 285.96% | |
| 1y | 254.84% |
| Open | 4.65 | Prev Close | 4.68 | Low | 4.28 | High | 4.66 | Mkt Cap | 166.04M |
| Vol | 442.13K | Avg Vol | 240.21K | EPS | -0.99 | P/E | N/A | Forward P/E | -1.17 |
| Beta | -0.22 | Short Ratio | 0.82 | Inst. Own | 52.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 5.53 | 200-d Avg | 3.85 | 1yr Est | 2.67 |
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmac
I rate AN2 Therapeutics a speculative buy, with a risk-adjusted base-case valuation of approximately
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biophar
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the disc
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
The Russell 2000 hits a record high as small caps outperform the Nasdaq 100, led by three companies,
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the dis
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
NEW YORK, July 20, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating A
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy ra
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc
AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel sma
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally in
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharm
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perf
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel sm
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analy
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
AN2 Therapeutics Inc. (NASDAQ: ANTX) shares were down during Wednesday's premarket session in a vola
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the clinical-stage bio
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expect
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightl
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reporte
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points o
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday.
Friday's session saw 100 companies set new 52-week lows.
On Thursday, 498 companies reached new 52-week lows.
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesda
Gainers
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28